Researchers from MedGenome, Genentech, and multiple international institutions found potentially actionable alterations in more than 200 gallbladder cancer samples.
The prospective study will combine real-world, clinical, and genomic data to streamline lung cancer clinical trials and find treatment-response biomarkers.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
By identifying core venom toxin genes with Indian cobra genomic and transcriptomic data, researchers hope to set the stage for future antivenom production based on synthetic venom.
In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.
The project has sequenced more than 1,700 individuals from across Asia to high coverage in order to bolster the representation of Asians in genomic research.
